The immunotherapy company, which is backed and partnered by Sorrento, secured almost $60m in funding in December 2014.
Conkwest, a US-based immunotherapy company that counts pharmaceutical firm Sorrento Therapeutics among its investors, filed for a $172.5m initial public offering on Nasdaq on Friday.
Founded in 2002 as ZelleRx, Conkwest is working on immunotherapy treatments for cancer, infectious diseases and inflammatory diseases.
The proceeds from the offering will support Phase 1 and 2 clinical trials for drug candidates covering Merkel cell carcinoma, solid tumours, acute myeloid leukaemia and solid tumour haematological cancers, and to establish a manufacturing facility.
…
